Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 10/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052623 | 0.88 | PPIA (0.53) | PPIALTA4HMAPK14SGMS2 | |
| SCHEMBL5740565 | 0.85 | LTA4H (0.55) | PPIALTA4HMAPK14SGMS2BRD4 | |
| SCHEMBL21439550 | 0.85 | PPIA (0.47) | PPIALTA4HMAPK14SGMS2BRD4 | |
| SCHEMBL31757763 | 0.82 | L3MBTL1 (0.56) | SGMS2BRD4RXRAKMT2A | |
| SCHEMBL2988197 | 0.82 | L3MBTL1 (0.56) | SGMS2BRD4RXRAKMT2A | |
| SCHEMBL534151 | 0.82 | MAPT (0.48) | KMT2A | |
| SCHEMBL18836470 | 0.82 | LTA4H (0.51) | PPIALTA4HMAPK14SGMS2BRD4 | |
| SCHEMBL27259858 | 0.82 | MAPT (0.53) | KMT2A | |
| SCHEMBL1178950 | 0.81 | LTA4H (0.60) | PPIALTA4HMAPK14SGMS2 | |
| SCHEMBL11179020 | 0.80 | PPIA (0.55) | PPIALTA4HMAPK14SGMS2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553845-B2 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2009-06-30 | — | — | US | disclosed |
| US-7553845-B2 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2009-06-30 | — | — | US | disclosed |
| US-7553845-B2 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2009-06-30 | — | — | US | disclosed |
| US-20060199962-A1 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199962-A1 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | FGF1, FGF2, FGFR1 | PPIA 3925/4885LTA4H 3758/4885MAPK14 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.